[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551365":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":25,"responsibleParty":48,"collaborators":18,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":18,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":18,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":18,"overallStatus":28,"whyStopped":18,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"acute normovolemic hemodilution group (ANH group)","EXPERIMENTAL","The ANH process was initiated after tracheal intubation. After completion of ANH, goal-directed fluid therapy will begin until the end of the surgery.",[13],"Procedure: acute normovolemic hemodilution",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard Group (STD group)","NO_INTERVENTION","After tracheal intubation, goal-directed fluid therapy will be implemented until the end of the surgery.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"PROCEDURE","acute normovolemic hemodilution","The ANH was conducted with more than 8 ml\u002Fkg of whole blood drawn from an internal jugular introducer by gravity and collected into standard sterile blood storage bags containing citrate phosphate-dextrose anticoagulant. The allowable blood loss was capped according to the preoperative hemoglobin, estimated blood volume, and the target hemoglobin (10 g\u002FdL). The collected blood was simultaneously replaced by an equal volume of succinyl gelatin solution via at least one large bore peripheralvenous catheter to maintain hemodynamic stability.",[9],[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"The Second Affiliated Hospital of Zhejiang University anesthesiology department","RECRUITING","Hangzhou","Zhejiang","310000","China","CN",{"type":35,"coordinates":36},"Point",[37,38],120.16142,30.29365,{"lat":38,"lon":37},[41,46],{"name":42,"role":43,"phone":44,"phoneExt":18,"email":45},"Min Yan, Doctor","CONTACT","15888210247","zryanmin@zju.edu.cn",{"name":42,"role":47,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100551365","the-effect-of-acute-normovolemic-hemodilution-in-bone-tumor-surgery-100551365",false,"NCT06459141","The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery","The Effect of Acute Normovolemic Hemodilution on Intraoperative Allogeneic Transfusion in Bone Tumor Surgery: a Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n1. age 18 to 75 years;\n2. undergoing elective bone tumor resection surgery;\n3. preoperative hemoglobin ≥11 g\u002FdL;\n\nExclusion Criteria:\n\n1. using a tourniquet;\n2. palliative operation or minimally invasive surgery;\n3. BMI\\\u003C18.5 or \\>30Kg\u002Fm\\^2;\n4. international normalized ratio (INR) \\>1.5 or platelet count \\\u003C100 × 10\\^9\u002FL;\n5. cardiopulmonary insufficiency;\n6. hepatic and renal dysfunction;\n7. active infectious disease;\n8. allergy to succinyl gelatin;\n9. pregnancy;\n10. declined participation in the study or declined blood transfusion","ALL","18 Years","75 Years",{"count":61,"type":62},150,"ESTIMATED","INTERVENTIONAL",[65],"NA","The prevention of intraoperative allogenetic blood transfusion has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone cancer surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial. The HEAL trial will assess whether ANH will reduce the volume of intraoperative allogeneic red blood cell transfusion in patients undergoing bone cancer surgery.",[68,69,70,71],"Acute Normovolemic Hemodilution","Bone Tumor","Goal-Directed Fluid Therapy","Transfusion","2026-06-22",{"date":74,"type":75},"2026-06-25","ACTUAL",{"date":77,"type":75},"2024-06-07",{"date":79,"type":62},"2028-05",{"name":5,"class":6},1]